A retrospective study of efficacy of tofacitinib combined with bDMARDs in the treatment of rheumatoid arthritis patients with inadequate response to bDMARDs.
Jie ChangGang WangPublished in: International journal of rheumatic diseases (2024)
Our findings offer some evidence, supporting the effectiveness and safety of combining bDMARD with JAKi tofacitinib in RA patients who have an inadequate response to bDMARD monotherapy. This combination effectively manages disease activity while maintaining a relatively low and manageable incidence of adverse events. Further prospective randomized controlled trials with large sample sizes are anticipated to provide evidence-based medical support.
Keyphrases
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- rheumatoid arthritis patients
- end stage renal disease
- systemic lupus erythematosus
- randomized controlled trial
- interstitial lung disease
- juvenile idiopathic arthritis
- newly diagnosed
- chronic kidney disease
- ejection fraction
- healthcare
- peritoneal dialysis
- prognostic factors
- systematic review
- meta analyses